Glaxosmithkline has a share of around 5% of the world’s pharmaceutical market, aiming to tackle 3 of the ‘priority’ diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.
Remember you are trying to beat the FTSE on a P/E, and also keep risk to a mimum, and dividends mean nothing. If you invest in a high dividend player like this and the markets plummet on bad news, this share goes down with them as well. It will generally take twice as long for this to steam ahead as others to get back to the same footing as before.
16 May '13
If you hold this share, like I have for 4.5years, accumulate shares on a dip if you like GSK. It is an expensive stock to peers, and I can only see single digit growth. I own Novartis ADR for nearly 6years and things only get better with this bemometh, also JNJ and very small holding of 250 in AZN.
12 May '13
10 May '13
back at 1688 if you include the divi
10 May '13
"The FDA approval of BREO ELLIPTA brings an important inhaled, once-daily maintenance therapeutic option to COPD patients and doctors across the United States," said Rick E Winningham, Chief Executive Officer of Theravance. "After more than a decade of joint respiratory research and development, the approval is a very important milestone for Theravance and GSK."
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.